Jpmorgan Chase & CO Baudax Bio, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$0.68 - $1.87 $88 - $243
-130 Reduced 90.28%
14 $0
Q1 2022

May 11, 2022
BUY
$1.58 - $8.47 $227 - $1,219
144 New
144 $0

About Baudax Bio, Inc.

BXRX Quotes by TradingView
  • Ticker BXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,003,700
  • Market Cap $200K
  • Description
  • Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuro...
More about BXRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email